German Drug Price Hikes Could Cost Insurers Billions
A new Harvard study reveals that proposed drug price hikes in Germany could cost health insurers an extra $6.2 billion annually. The research suggests such increases would offer little financial relief to the United States while driving up spending globally.
Xurve View
Insights:
Xurve View
Germany's statutory health insurers face $6.2 billion in additional annual costs if drug prices rise to meet United States policy pressures, a Harvard Medical School study showed on Wednesday.
